(Q34293419)

1 August 2017

title

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis (English)

1 reference

1 August 2017

0 references

3

Hagop Kantarjian

1 reference

1 August 2017

7

Srdan Verstovsek

1 reference

1 August 2017

6

Jorge Cortes

1 reference

1 August 2017

1

Elias Jabbour

1 reference

1 August 2017

5

Sherry Pierce

1 reference

1 August 2017

4

Lingsha Zhou

1 reference

1 August 2017

Deborah Thomas

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

26 May 2011

1 reference

1 August 2017

1 reference

1 August 2017

volume

118

1 reference

1 August 2017

issue

4

1 reference

1 August 2017

page(s)

899-902

1 reference

Thalidomide and lenalidomide in primary myelofibrosis

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Risk of thrombosis with lenalidomide and its prevention with aspirin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Pathogenesis of myelofibrosis with myeloid metaplasia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4186644

Thalidomide therapy for myelofibrosis with myeloid metaplasia

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21622644

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21622644

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2010-12-325589

1 reference

1 August 2017

1 reference

1 August 2017

1 reference